MIRA INFORM REPORT

 

 

Report Date :

01.04.2013

 

IDENTIFICATION DETAILS

 

Name :

GENIX PHARMA (PRIVATE) LIMITED

 

 

Formerly Known as:

Karmann Pharma (Private) Limited

 

 

Registered Office :

B-44 & 45, Korangi Creek Road, Karachi - 75190

 

 

Country :

Pakistan

 

 

Year of Establishments:

1994

 

 

Com. Reg. No.:

0033360

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

138

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory 

 

 

Payment Behaviour :

Slow

 

 

Litigation :

Clear 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

pakistan - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to more than 13% for 2011, before declining to 9.3% at year-end. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in the second half of 2011, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging 2.9% per year from 2008 to 2011. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing population. Other long term challenges include expanding investment in education and healthcare, and reducing dependence on foreign donors.

 

Source : CIA

 

 

 

                                   

Business Name

 

GENIX PHARMA (PRIVATE) LIMITED

 

Full Address       

 

Registered Address & Factory

B-44 & 45, Korangi Creek Road, Karachi - 75190, Pakistan

                       

Tel #

92 (21) 111-101-011

Fax #

92 (21) 111-101-022

Website

www.genixpharma.com

 

 

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1994

c.

Registration #

0033360

 

 

Overseas Branch

 

Address

2 College Court, Gildersom, Leeds, LS27 7WF, United Kingdom

Tel #

0845 8381122

Fax #

0845 8381133

 

 

Auditors

 

Rauf Ayub & Co.

(Chartered Accountants)

504, Business Plaza, Mumtaz Hasan Road, Karachi, Pakistan

 

 

Legal Status & Change of Name

 

Subject Company was incorporated by the name of “Karmann Pharma (Private) Limited” then afterwards it name was changed to “Genix Pharma (Private) Limited”

 

 

 

Authorized Capital

Rs. 50,000,000/- divided into 5,000,000 shares of Rs. 10/- each

Issued & Paid up Capital

Rs. 50,000,000/- divided into 5,000,000 shares of Rs. 10/- each

 

 

Details of Chief Executive / Directors

 

Names

Nationality

Address

Occupation

Designation

Mr. Mohammad Shahbaz Sharif

 

 

Mr. Mohammad Israr Sharif

 

 

Mr. Tariq Anjum

 

 

Pakistani

 

 

 

Pakistani

 

 

 

Pakistani

 

 

B-44 & 45, Korangi Creek Road, Karachi

 

B-44 & 45, Korangi Creek Road, Karachi

 

B-44 & 45, Korangi Creek Road, Karachi

Business

 

 

 

Business

 

 

 

Service

 

 

Chief Executive

 

 

 

Director

 

 

 

Company’s Secretary

 

 

 

 

Shareholders                 

 

Names of Shareholders

Mr. Mohammad Shahbaz Sharif

 

Mr. Mohammad Israr Sharif

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

            None                                             

           

B.         Associated Companies

(1) Genix Healthcare Ltd. U.K.

 

 

Products / Services

 

Manufacture & marketing of Pharmaceutical Products including Antibiotics, Antiulcerants, Haemostatics, Immunosuppressant and third generation Cephalosporin Parental / Oral Formulations by its brand name of GEN-M, GEN-ART, ZOLERIC, RESPICARE, OXIFECT, S-FLOX, EFECIP, GENOVAX, GRAT, GENFIX

 

 

Number of Employees

           

138

 

 

Trade Suppliers

(Foreign)

 

·         ZHEJIANG JINGXIN PHARMACEUTICAL IMPORT & EXPORT, CHINA.

JIANGXI. MEDICINES AND HEALTH PRODUCTS, CHINA.

ZHEJIANG CHEMICALS IMPORT AND. EXPORT CORPORATION, CHINA.

HETERO DRUGS LIMITED, U.A.E.

 

 

Annual Production Volume

 

The capacity and production of the company’s plant is indeterminable as it involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2011

170,000,000/- (Estimated)

 

 

Authorized Distributors

 

In Karachi, Multan, Faisalabad, Rawalpindi, Lahore & Peshawar

 

 

Bankers

 

(1) National Bank of Pakistan, Pakistan.

     (Mortgage obtained:  PKR 19,391,000/-)

(2) Askari Bank Limited, Pakistan.

(3) Soneri Bank Limited, Pakistan.

(4) Bank Alhabib Limited, Pakistan.

 

 

Memberships

 

·         Pakistan Pharmaceutical Manufacturers Association.(PPMA)

Karachi Chamber of Commerce & Industry.(KCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 98.80

UK Pound

1

           Rs. 149.00

Euro

1

           Rs. 127.50

 

 

Comments

 

Subject Company was established in 1994 and is engaged in manufacture & marketing of Pharmaceutical Products. Directors are reported as qualified, experienced and resourceful businessmen. Trade relations are reported as fair. Subject can be considered for normal business dealings at usual trade terms and conditions.

 

 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.54.39

UK Pound

1

Rs.82.32

Euro

1

Rs.69.54

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.